Cellyan Biotechnology Co., Ltd. Form 6-K Summary
Business Context and Reporting Period
Cellyan Biotechnology Co., Ltd. (formerly Hong Kong Pharma Digital Technology Holdings Limited), a Cayman Islands exempted company, filed this Form 6-K on March 18, 2026. The filing provides unaudited interim consolidated financial statements for the six-month period ended September 30, 2025, and comparative data for the same period in 2024.
Key Financial Metrics
The provided text serves as a cover page and exhibit index. It does not contain the actual financial data. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not available in this excerpt.
Material Changes
The filing text does not provide specific details regarding material changes in financial performance or operations compared to the prior period. The detailed Operating and Financial Review is listed as Exhibit 99.2 but is not included in the input text.
Guidance, Outlook, and Risks
Management commentary, future guidance, risk factors, and contingencies are referenced as being contained within Exhibit 99.2 (Operating and Financial Review and Prospects). No specific outlook or risk details are present in the provided cover page text.
Investor Verification Checklist
- Verify the full content of Exhibit 99.1 to obtain actual revenue, net income, and cash flow figures for the six months ended September 30, 2025.
- Review Exhibit 99.2 for management's discussion of operational changes, liquidity status, and future prospects.
- Confirm the company's current debt obligations and working capital position, as these are not disclosed in the cover page.
- Check for any unusual items or contingencies detailed in the full interim financial statements.